Consumer Insights
Uncover trends and behaviors shaping consumer choices today
Procurement Insights
Optimize your sourcing strategy with key market data
Industry Stats
Stay ahead with the latest trends and market analysis.
Explore Our Diverse Range Of Offerings
From detailed reports to experts services offered in 15+
Industry Domains
Add 2 More Reports For 20% off
Report Overview
The renal cell carcinoma market was valued at USD 5.00 Billion in 2025. It is poised to grow at a CAGR of 4.22% during the forecast period of 2026-2035, and reach USD 7.56 Billion by 2035. The market growth is driven by increasing incidence of renal cell carcinoma, rising adoption of targeted therapies, immunotherapy advancements, and expanding clinical research improving treatment outcomes globally.
Latest News on the Renal Cell Carcinoma Market (2026)
- In April 2026, a Phase 3 BIOFRONT trial was initiated to evaluate microbiome-based therapy improving immunotherapy outcomes in advanced RCC patients.
- In April 2026, Kura Oncology reported positive data for darlifarnib plus cabozantinib, showing tumor response in previously treated renal cell carcinoma patients.
- In October 2025, lenvatinib plus everolimus demonstrated improved outcomes as second-line treatment for advanced renal cell carcinoma in clinical studies.
Key Market Trends and Insights
- By indication type, clear cell RCC dominated the market, accounting for approximately 75% share in the historical period.
- By treatment type, targeted therapy held the largest market share of around 45% in the historical period.
- By country, the United States dominated the market with over 40% share in the historical period.
Market Size and Forecast
- Market Size (2025): USD 5.00 Billion
- Projected Market Size (2035): USD 7.56 Billion
- CAGR (2026-2035): 4.22%
Compound Annual Growth Rate
4.22%
Value in USD Billion
2026-2035
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Renal Cell Carcinoma Market Overview
The market is experiencing steady growth due to the rising incidence of kidney cancer and increasing adoption of targeted therapies and immunotherapies. Advancements in precision medicine and biomarker-driven treatment approaches are improving patient outcomes. Expanding clinical trials, strong pipeline development, and growing healthcare investments are further supporting market expansion across developed and emerging regions globally. The market reached a value of approximately USD 5.00 Billion in 2025.
Renal Cell Carcinoma Market Growth Drivers
Rising Targeted Therapy Innovations Driving the Market Development
Growing demand for precision oncology and expanding late-stage pipelines are driving market development. For instance, in October 2025, researchers reported that lenvatinib plus everolimus demonstrated improved outcomes as a second-line treatment for advanced renal cell carcinoma. This progress is enhancing therapeutic strategies and supporting biomarker-guided evaluation, including glomerular filtration rate (GFR), strengthening long-term market development.
Renal Cell Carcinoma Market Trends
Key trends shaping the market include rising adoption of immunotherapies, increasing use of targeted therapies, expanding clinical trials, and growing focus on personalized treatment approaches globally.
Rising Clinical Trial Advancements Supporting the Market Expansion
The rising incidence of kidney cancer and increasing investment in targeted therapies are accelerating market growth. For instance, in April 2026, Kura Oncology, Inc. reported positive clinical data for darlifarnib combined with cabozantinib, demonstrating meaningful tumor response in previously treated renal cell carcinoma patients. This advancement is strengthening precision treatment adoption and supporting monitoring approaches using creatinine, driving market growth.
Renal Cell Carcinoma Market Segmentation
Market Breakup by Indication Type
- Chromophobe RCC
- Papillary RCC
- Clear Cell RCC
- Others
Market Breakup by Treatment Type
- Surgery
- Chemotherapy
- Targeted Therapy
- Ablation
- Medication
- Others
Market Breakup by Diagnosis
- Biopsy
- Ultrasound
- Blood Test
- Nephrectomy
- CT Scan
- Urine Tests
- Others
Market Breakup by Dosage Form
- Capsule
- Tablets
- Injections
- Others
Market Breakup by Route of Administration
- Oral
- Parenteral
- Others
Market Breakup by End User
- Hospitals
- Specialty Clinics
- Homecare
- Others
Market Breakup by Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online pharmacy
- Others
Market Breakup by Country
- United States
- United Kingdom
- Germany
- France
- Italy
- Spain
- Japan
- India
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Renal Cell Carcinoma Market Share
Targeted Therapy Expected to Dominate the Market Segment by Treatment Type
The targeted therapy segment led the market, accounting for around 45% share in the historical period. Its dominance is driven by strong clinical efficacy, widespread adoption, and continued innovation in precision oncology. Increasing use of biomarker-driven approaches, including glomerular filtration rate (GFR) assessment, is improving treatment selection and supporting sustained growth across advanced RCC management globally.
Purchase the Regional Overview for USD 1099
If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.
Purchase the Regional Overview for USD 1099
If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.
Purchase the Regional Overview for USD 1099
If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Renal Cell Carcinoma Market Analysis by Region
The United States dominated the market with over 40% share in the historical period. This leadership is supported by advanced healthcare infrastructure, strong reimbursement systems, and high adoption of novel therapies. Growing emphasis on early detection and disease monitoring, including the use of creatinine, is enhancing clinical outcomes and reinforcing the country’s position in the global RCC market.
Leading Players in the Renal Cell Carcinoma Market
The key features of the market report comprise patent analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:
Bausch Health Companies Inc.
Headquartered in Laval, Canada, and founded in 1959, Bausch Health Companies Inc. focuses on specialty pharmaceuticals, primarily in gastroenterology, dermatology, and ophthalmology. The company has limited direct exposure to renal cell carcinoma but supports oncology care through adjunct therapies. Its broader clinical focus aligns with monitoring disease burden, including indicators such as creatinine in patient management settings globally.
Abbott
Abbott is a global healthcare company headquartered in Abbott Park, Illinois, specializing in diagnostics, medical devices, nutrition, and branded generic pharmaceuticals. In the renal cell carcinoma market, the company supports oncology care through advanced diagnostic solutions and biomarker monitoring technologies that aid in disease detection and treatment management. Abbott’s strong focus on precision diagnostics and patient monitoring contributes to improved clinical decision-making and enhances overall cancer care outcomes across healthcare settings.
Merck KGaA
Merck KGaA, headquartered in Darmstadt, Germany, and founded in 1668, is actively involved in oncology, including renal cell carcinoma treatment through immunotherapy combinations such as Bavencio. The company continues to expand clinical research in RCC. Its oncology strategy supports biomarker-driven treatment approaches, including evaluation of glomerular filtration rate (GFR) for improved patient stratification and therapeutic monitoring globally.
AbbVie Inc.
AbbVie Inc., headquartered in North Chicago, Illinois, USA, and founded in 2013, is a major biopharmaceutical company focused on oncology, immunology, and targeted therapies. While not a primary RCC leader, its oncology pipeline contributes to combination strategies. The company’s research supports biomarker-based monitoring approaches, including the use of acute kidney injury biomarker indicators in clinical oncology settings.
Other key players in the market are Johnson & Johnson Services, Inc., AstraZeneca PLC, Merck & Co., Inc., Mylan N.V., Eli Lilly and Company, and Pfizer, Inc., and Bayer AG.
*Please note that this is only a partial list; the complete list of key players is available in the full report. Additionally, the list of key players can be customized to better suit your needs.*
Key Questions Answered in the Renal Cell Carcinoma Market Report
- What was the renal cell carcinoma market value in 2025?
- What is the renal cell carcinoma market forecast outlook for 2026-2035?
- What major factors aid the demand for renal cell carcinoma market?
- How has the market performed so far, and how is it anticipated to perform in the coming years?
- What are the market’s major drivers, opportunities, and restraints?
- What are the major renal cell carcinoma market trends?
- Which indication type is expected to dominate the market segment?
- Which treatment type is expected to dominate the market segment?
- Which diagnosis is expected to dominate the market segment?
- Which dosage form is expected to dominate the market segment?
- Which route of administration is expected to dominate the market segment?
- Which end user is expected to dominate the market segment?
- Which distribution channel is expected to dominate the market segment?
- Who are the key players in the renal cell carcinoma market?
- What are the current unmet needs and challenges in the market?
- How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?
Pricing Plans
Upto 15% Off
USD
-
$3299 $2969
-
$5499 $4949
-
$6999 $5949
-
$8199 $6969
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Report Summary
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
| REPORT FEATURES | DETAILS |
| Base Year | 2025 |
| Historical Period | 2019-2025 |
| Forecast Period | 2026-2035 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Indication Type |
|
| Breakup by Treatment Type |
|
| Breakup by Diagnosis |
|
| Breakup by Dosage Form |
|
| Breakup by Route of Administration |
|
| Breakup by End User |
|
| Breakup by Distribution Channel |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
Datasheet
One User
USD 3,299
USD 2,969
tax inclusive*
- Selected Segments
- Printing Restrictions
- Excel Spreadsheet Delivered via Email
- Full Report
- Periodic Updates
- Post Sales Analysts Support
- Unlimited Prints
Single User License
One User
USD 5,499
USD 4,949
tax inclusive*
- All Segments
- Printing Restrictions
- PDF Delivered via Email
- Custom Report Layout
- Post Sales Analysts Support
- Periodic Updates
- Unlimited Prints
Five User License
Five User
USD 6,999
USD 5,949
tax inclusive*
- All Segments
- Five Prints Available
- PDF Delivered via Email
- Limited Free Customization
- Post Sales Analyst Support
- Custom Report Layout
- Periodic Updates
- Unlimited Prints
Corporate License
Unlimited Users
USD 8,199
USD 6,969
tax inclusive*
- All Segments
- Unlimited Prints Available
- PDF & Excel Delivery via Email
- Limited Free Customization
- Post Sales Analysts Support
- Discount On Next Update
- Custom Report Layout
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Bundle Type
Flash Bundle
20% OFF
Number of Reports: 3
Small Business Bundle
25% OFF
Number of Reports: 5
Growth Bundle
30% OFF
Number of Reports: 8
Enterprise Bundle
35% OFF
Number of Reports: 10
Overview
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 80 Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 100 Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
- 3 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- Complimentary Excel Data Set
- PPT Version of the Report
- Power BI Dashboards
- License Upgrade
- Free Analyst Hours
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
- 5 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- Complimentary Excel Data Set
- PPT Version of the Report
- Power BI Dashboards
- License Upgrade
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
- 8 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- License Upgrade
- Free Analyst Hours - 80 Hours
- Power BI Dashboards
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
- 10 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- License Upgrade
- Power BI Dashboards
- Free Analyst Hours - 100 Hours
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Strategic Solutions for Informed Decision-Making
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
